Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...

For those dealing with fatty liver disease, there’s welcome news to report. Earlier this year, the United States Food and Drug Administration (FDA) approved the first and only fatty liver disease drug ...

Fatty liver disease, particularly Non-Alcoholic Fatty Liver Disease (NAFLD), is a growing health concern worldwide, affecting an estimated 30.2% of the world's population. Prevalence varies by region, ...

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic fatty liver diseases (NAFLD) into more severe forms of liver disease by ...

GLP-1RAs and SGL2 inhibitors were associated with lower risks for NAFLD and NASH among patients with type 2 diabetes. Newer classes of glucose-lowering agents may reduce risk for liver disease among ...

NAFLD is a chronic liver disease caused by fat buildup in the liver, even with little to no alcohol use. Risk factors for NAFLD include being overweight or obese, having type 2 diabetes, high ...

Taking daily aspirin may prevent progression of nonalcoholic fatty liver disease (NAFLD) to liver fibrosis and nonalcoholic steatopepatitis (NASH), according to a study published online May 8 in ...